Unicycive Therapeutics, Inc. Annual report [Section 13 and 15(d), not S-K Item 405]

Audit Information	12 Months Ended
Audit Information	Dec. 31, 2025
Auditor [Table]
Auditor Name	GRASSI & CO., CPAs, P.C.
Auditor Firm ID	606
Auditor Location	Jericho, New York
Auditor Opinion [Text Block]	Opinion on the Financial Statements We have audited the accompanying balance sheets of Unicycive Therapeutics, Inc. (the “Company”) as of December 31, 2024 and 2025, and the related statements of operations and comprehensive loss, mezzanine equity and stockholders’ (deficit) equity, and cash flows for each of the years then ended, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2025, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.